Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2015

Open Access 01-12-2015 | Erratum

Erratum: TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion

Authors: Bin Li, Ming-Zhu Huang, Xiao-Qiang Wang, Bang-Bao Tao, Jun Zhong, Xu-Hui Wang, Wen-Chuan Zhang, Shi-Ting Li

Published in: Journal of Hematology & Oncology | Issue 1/2015

Login to get access

Excerpt

It has been brought to our attention that in Fig. two of the article [1], the immunoblots in the middle panel were incorrectly labeled as TREM2 instead of TMEM140. The correct figure is included below (Fig. 1), in which the immunoblots in the middle panel are labeled as TMEM140. This labeling correction does not affect the results or interpretation of the results. We apologize for this error.
Literature
1.
go back to reference Li B, Huang MZ, Wang XQ, Tao BB, Zhong J, Wang XH, et al. TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion. J Hematol Oncol. 2015;8(1):89. doi:10.1186/s13045-015-0187-4. Li B, Huang MZ, Wang XQ, Tao BB, Zhong J, Wang XH, et al. TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion. J Hematol Oncol. 2015;8(1):89. doi:10.​1186/​s13045-015-0187-4.
Metadata
Title
Erratum: TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion
Authors
Bin Li
Ming-Zhu Huang
Xiao-Qiang Wang
Bang-Bao Tao
Jun Zhong
Xu-Hui Wang
Wen-Chuan Zhang
Shi-Ting Li
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-015-0199-0

Other articles of this Issue 1/2015

Journal of Hematology & Oncology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine